Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $7.06

Shares of Vor Biopharma Inc. (NYSE:VOR) have earned an average recommendation of “Hold” from the ten analysts that are currently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $7.06.

Several research firms have commented on VOR. Stifel Nicolaus lowered their target price on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. JMP Securities reiterated a “market perform” rating and set a $6.00 price objective on shares of Vor Biopharma in a research note on Friday, May 9th. Citizens Jmp downgraded Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 9th. Oppenheimer reaffirmed an “outperform” rating and set a $8.00 price target on shares of Vor Biopharma in a research note on Friday, March 21st. Finally, Wedbush reissued a “neutral” rating and issued a $0.40 price objective (down previously from $7.00) on shares of Vor Biopharma in a research note on Thursday, May 8th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in shares of Vor Biopharma in the 4th quarter worth $33,000. Money Concepts Capital Corp boosted its position in shares of Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after purchasing an additional 26,535 shares during the period. Virtu Financial LLC purchased a new position in Vor Biopharma in the 4th quarter worth about $60,000. XTX Topco Ltd purchased a new position in Vor Biopharma in the 4th quarter worth about $80,000. Finally, Goldman Sachs Group Inc. lifted its stake in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares in the last quarter. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Stock Up 3.5%

Shares of NYSE VOR opened at $0.18 on Friday. The stock has a market cap of $22.09 million, a P/E ratio of -0.11 and a beta of -0.21. The firm’s 50-day simple moving average is $0.63 and its 200 day simple moving average is $0.95. Vor Biopharma has a fifty-two week low of $0.13 and a fifty-two week high of $1.83.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.